Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Medtech
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Evaluate Vantage Homepage
Pharmaceutical Companies
Nerviano Medical Sciences
April 28, 2020
AACR 2020 – Not so fast, Trovagene
December 22, 2017
Ignyta investors have the last laugh
September 09, 2016
Snippet roundup: Gilead’s Parp interest, Futura and Retrophin get data boost
April 18, 2016
AACR – Loxo and Ignyta clash on novel kinase mechanism
March 18, 2015
Ignyta: boldly going where no one has gone before
October 01, 2014
Therapy focus – Leukaemia opportunity gives FLT a chance to take flight
August 01, 2012
Therapeutic focus – Gleevec generic set to change the leukaemia landscape
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 24, 2022
EVALUATE VANTAGE 2022 プレビュー 分析ハイライト
January 24, 2022
Evaluate Vantage 2022 プレビュー 投資家インタビュー（日本語版）
Editor's Picks
January 05, 2022
In 2021 it paid to stay private when the chips were down
January 07, 2022
Big beasts drive biopharma valuations higher in 2021
December 20, 2021
Another failure heaps more pressure on Novartis
January 04, 2022
Days of reckoning for immune checkpoint blockers
November 22, 2021
The bubble bursts for biotech stocks
